Liraglutide

Liraglutide scored 5.2 / 10 (⚖️ Neutral) on the BioHarmony scale as a Peptide pharmaceutical (once-daily GLP-1 receptor agonist).

Liraglutide is a once-daily prescription GLP-1 receptor agonist. In the 3,731-person SCALE trial, 3.0 mg with lifestyle counseling produced 8.4 kg mean weight loss versus 2.8 kg on placebo over 56 weeks, and in LEADER it lowered major cardiovascular events in high-risk type 2 diabetes (HR 0.87). A 2025 Cochrane review rated most obesity outcomes low to moderate certainty.

Overall5.0–5.5⚖️ NeutralContext-dependent
Your Score🔒Take the quiz →
Blood Sugar / Glycemic Control 7.5–8.0 Metabolic Health 7.0–7.5 Cardiovascular 7.0–7.5 Body Composition / Fat Loss 6.5–7.0 Kidney Function 5.5–6.0
📅 Scored October 12, 2026·BioHarmony v2.0·Rev 5

What is Liraglutide?

Liraglutide is a once-daily injectable GLP-1 receptor agonist, prescribed for type 2 diabetes and, at a higher dose, for chronic weight management in adults and in adolescents 12 and older who weigh more than 60 kg and have obesity. It was the first GLP-1 drug with a positive cardiovascular outcome trial. In the 56-week SCALE trial, 3,731 adults on liraglutide 3.0 mg plus lifestyle counseling lost 8.4 kg on average versus 2.8 kg on placebo (Pi-Sunyer 2015). An independent Cochrane review later confirmed that liraglutide raises the likelihood of meaningful weight loss, while rating several other obesity outcomes low or very low certainty. The overall score of 5.0–5.5/10 reflects that balance: solid evidence and real outcome data in type 2 diabetes, set against daily injections, common nausea, a serious if rare pancreatitis risk, and weight that often returns after stopping. Everything here about dosing describes label-guided, prescriber-supervised use.

Liraglutide works by activating the GLP-1 receptor, the target of a gut hormone released after meals. A fatty-acid side chain lets it bind albumin, which stretches its half-life to about 13 hours. The weekly drugs semaglutide and the dual agonist tirzepatide use the same pathway with longer action.

Terminology

Liraglutide research uses a handful of terms that change how the numbers should be read. The first distinction is between the labeled uses: the diabetes dose tops out at 1.8 mg daily, while the weight-management dose is 3.0 mg daily, and results from one don't transfer neatly to the other. The second is between surrogate markers, such as HbA1c or weight, and hard outcomes, such as heart attacks or death. LEADER measured hard outcomes, but only in people with type 2 diabetes and high cardiovascular risk. The third is evidence certainty: a Cochrane review grades how confident we can be in each result, so a drug can have moderate-certainty evidence for one outcome and very-low-certainty evidence for another. The fourth is between rodent and human findings, since the boxed thyroid warning for liraglutide comes from rats and mice. Keeping these lines clear prevents the most common misreadings of liraglutide.

  • GLP-1: Glucagon-like peptide-1, a gut hormone that raises insulin after meals and signals fullness.
  • GLP-1 receptor agonist: A drug that activates the GLP-1 receptor, such as liraglutide or semaglutide.
  • HbA1c: A blood test reflecting average glucose over roughly three months.
  • MACE: Major adverse cardiovascular events, usually cardiovascular death, nonfatal heart attack and nonfatal stroke.
  • Hazard ratio (HR): The relative rate of an event in one group versus another; 0.87 means 13% lower.
  • GRADE certainty: The Cochrane rating of how confident reviewers are in a result, from high to very low.
  • MTC: Medullary thyroid carcinoma, a cancer of thyroid C-cells.
  • MEN 2: Multiple endocrine neoplasia type 2, an inherited syndrome that raises MTC risk.
  • AHI: Apnea-hypopnea index, the number of breathing interruptions per hour of sleep.
  • NASH: Non-alcoholic steatohepatitis, liver inflammation driven by fat, now often called MASH.
  • BMI SDS: Body mass index standard deviation score, the pediatric measure of weight relative to age and sex.

How do you take Liraglutide?

Dosing & Protocols

Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.

View 1 route and 3 protocols

Routes & Forms

RouteFormClinical RangeCommunity Range
Subcutaneous injectionPrefilled multi-dose pen, once daily at any time of day Per FDA label: 0.6 to 1.8 mg daily for type 2 diabetes; 0.6 mg daily escalated weekly to 3.0 mg daily for weight management Prescription-only. Dose and titration are set by the prescriber against the current label for the specific indication and age group. Patient reviews often describe staying at 1.2 to 1.8 mg or stepping back down after nausea (self-reported, not verified)

Protocols

Adult weight-management label titration (prescriber supervised) Clinical

Dose
0.6 mg daily, increased by 0.6 mg each week to 3.0 mg daily
Frequency
Once daily
Duration
Ongoing while benefit continues; the label advises evaluating weight 16 weeks after starting and stopping if loss is under 4% of baseline

Adults with obesity, or overweight with at least one weight-related condition. Reproduced for orientation only.

Adolescent weight-management label outline (pediatric specialist supervised) Clinical

Dose
0.6 mg daily escalated toward 3.0 mg daily; 2.4 mg daily permitted if 3.0 mg is not tolerated
Frequency
Once daily
Duration
Escalation may take up to 8 weeks; the label advises checking BMI after 12 weeks on the maintenance dose and stopping if BMI has not fallen at least 1%

Labeled only for ages 12 and older with body weight above 60 kg and obesity. Trials in younger children are research evidence, not a current weight-management label.

Type 2 diabetes label titration (prescriber supervised) Clinical

Dose
0.6 mg daily for 1 week, then 1.2 mg daily, increased to 1.8 mg if needed
Frequency
Once daily
Duration
Ongoing

Labeled for glycemic control in adults and children 10 and older with type 2 diabetes; insulin or sulfonylurea doses may need review to limit hypoglycemia.

How the score is calculated
Upside (weighted)
+2.73
Downside (harm ×1.4)
2.57
EV = 2.73 − 2.57 = 0.16 → Score = 5 + (0.16 / 4.00) × 5 = 5.2 / 10

How this score is calculated →

What are the benefits of Liraglutide?

Upside contribution: 2.73

DimensionWeightBandVisualWeighted
Efficacy25%Strong
0.975
Breadth15%Strong
0.630
Evidence25%Strong
1.000
Speed10%Strong
0.380
Durability10%Limited
0.200
Bioindividuality15%Strong
0.540
Total3.725
Baseline offset (constant)−1.000
Effective upside contribution2.725

Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.

Upside Rationale

Liraglutide's upside comes from moderate weight loss, reliable glucose lowering, and hard cardiovascular outcome data in high-risk type 2 diabetes. The strongest single finding is LEADER, where 9,340 people with type 2 diabetes at high cardiovascular risk had fewer major cardiovascular events on liraglutide, a hazard ratio of 0.87, and lower cardiovascular and all-cause death over a median 3.8 years (Marso 2016). In prediabetes, three years of treatment cut new diabetes diagnoses from 6% to 2%, although about half of participants left the study early (le Roux 2017). The boundary condition is population: the cardiovascular result belongs to high-risk diabetes, and the obesity evidence is rated more cautiously by independent reviewers. The trials measured benefit during treatment, and the evidence gathered here shows weight often drifting back after stopping. Its Alzheimer's trial missed its primary endpoint, so the brain-health interest around this class doesn't yet apply to liraglutide.

Efficacy (Strong): Liraglutide's clearest effect is weight loss beyond placebo of roughly 5 kg, or about 4.7% of body weight in the pooled Cochrane estimate, alongside an HbA1c reduction of about 1 percentage point in type 2 diabetes. The Cochrane review found liraglutide makes reaching 5% weight loss about twice as likely as placebo, with moderate certainty (Meza 2025). In type 2 diabetes the weight effect is smaller, 6.0% versus 2.0% on placebo in 846 patients (Davies 2015). That is a moderate-to-large clinical effect in the indicated populations.

Breadth of Benefits (Strong): Liraglutide carries named human endpoints across several domains: weight, glucose, diabetes prevention, cardiovascular death in high-risk diabetes, albuminuria and modest sleep apnea improvement. The LEADER renal analysis found a renal composite hazard ratio of 0.78, mainly through less new macroalbuminuria (Mann 2017). A small liver trial found more steatohepatitis resolution than placebo. Most of these effects share one root, weight and glucose improvement, and the heart failure trial was null, which keeps breadth below the top band.

Evidence Quality (Strong): Liraglutide has a large trial base, but independent reviewers rate it less confidently than its size suggests. The Cochrane review of 24 obesity trials and 9,937 participants graded the chance of reaching 5% weight loss moderate certainty, the pooled average weight change very low certainty, and serious adverse events low certainty, and noted that 22 trials were manufacturer-funded (Meza 2025). That review sets the ceiling for the obesity evidence here. LEADER adds strong outcome evidence for type 2 diabetes, and an academic-led Copenhagen trial gives partial independent replication of the weight effect.

Speed of Onset (Strong): Liraglutide changes appetite and post-meal glucose within days, and fasting glucose usually falls within one to two weeks. Weight loss is gradual, because the weight dose is titrated weekly over the first month and most of the loss accrues over several months. The adult label sets an evaluation 16 weeks after starting, so a person and prescriber know fairly early whether liraglutide is working, even though the full effect takes most of a year.

Durability (Limited): Liraglutide's weight benefit fades for many people after stopping. A pooled analysis of weight-management drugs found regain of about 0.4 kg per month after cessation (West 2026). Exercise changes that picture: one year after treatment ended, people who had combined liraglutide with supervised exercise weighed 5.1 kg less than those who had taken liraglutide alone, though only 109 participants attended that follow-up (Jensen 2024).

Bioindividuality Upside (Strong): A clear majority respond to liraglutide. In SCALE, 63.2% lost at least 5% of body weight and 33.1% lost more than 10%, while roughly a third lost less than 5%. People with type 2 diabetes tend to lose less weight. The most useful predictor is early response: the adult label advises stopping if weight loss is under 4% at 16 weeks after starting, and the adolescent label uses a BMI check after 12 weeks on the maintenance dose, which spares non-responders months of injections.

What are the risks & downsides of Liraglutide?

Downside contribution: 2.57 (safety risks weighted extra)

DimensionWeightBandVisualWeighted
Safety30%High
1.200
Side effects15%Moderate
0.390
Cost premium5%Moderate
0.130
Effort5%Low
0.100
Opportunity5%Low
0.120
Dependency15%High
0.525
Reversibility25%Low
0.425
Total2.890
Harm subtotal × 1.43.556
Opportunity subtotal × 1.00.350
Combined downside3.906
Baseline offset (constant)−1.340
Effective downside penalty2.566

Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.

Cost premium: premium over the cheapest legitimate route, not price.

Downside Rationale

Liraglutide's downside is dominated by one serious but rare intrinsic risk and one common nuisance. The serious risk is acute pancreatitis: the current label states that fatal and non-fatal hemorrhagic or necrotizing pancreatitis has been observed with GLP-1 receptor agonists including liraglutide (DailyMed 2026). The common burden is gastrointestinal: nausea affects about 39% on the weight dose versus 14% on placebo. People most exposed are those with a pancreatitis or gallbladder history, those also on insulin or sulfonylureas, and anyone with medullary thyroid carcinoma or MEN 2 in the family, who shouldn't use it. The thyroid C-cell tumor warning comes from rodents, and human studies disagree, so it's a contraindication to respect rather than a demonstrated human cancer cause. The remaining downside is practical: a daily injection, ongoing treatment, and stronger weekly options for weight loss.

Safety Risk (High): Liraglutide's labeled pancreatitis risk includes rare fatal hemorrhagic or necrotizing cases, an intrinsic, life-threatening harm even though it's uncommon. In LEADER, pancreatitis wasn't more frequent than on placebo, and the label also lists gallbladder disease, hypoglycemia with insulin or sulfonylureas, kidney injury from dehydration, heart rate increase and aspiration risk during anesthesia. A meta-analysis found gallbladder and biliary disease more common on GLP-1 drugs, with a relative risk of 2.29 in weight-loss trials (He 2022). In early 2026, FDA asked for the suicidal ideation warning to be removed (FDA 2026).

Side Effect Profile (Moderate): Gastrointestinal effects are the everyday cost of liraglutide. On the weight dose, nausea runs about 39% versus 14% on placebo and diarrhea about 21% versus 10%, mostly during titration. The Cochrane review found adverse events leading to withdrawal roughly twice as common as on placebo, though at very low certainty. Slower titration and smaller meals help many people, and the effects often ease over weeks, but for a meaningful minority they're the reason treatment ends.

Cost Premium (Moderate): This dimension measures the premium over the cheapest legitimate route to the same exposure, not the monthly price itself. A first generic referencing the diabetes product was approved in late 2024 (FDA 2024), which supports access for type 2 diabetes. No verified current price was available for this report, so the value here is an estimated judgment rather than a price claim.

Time/Effort Burden (Low): Liraglutide takes about a minute a day: one subcutaneous injection from a prefilled pen, at any time of day, with a weekly dose step during the first month for adult weight management. That daily rhythm is more demanding than a weekly injection, and missed doses for three or more days can mean restarting titration. Pairing it with resistance training and protein, which the evidence favors, adds effort beyond the injection itself.

Opportunity Cost (Low): For weight loss, a stronger alternative in the same category exists. In the STEP 8 head-to-head trial in adults without diabetes, weekly semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% on liraglutide 3.0 mg over 68 weeks, with half the discontinuation (Rubino 2022). Liraglutide still earns a place where a prescriber has a specific reason, such as its LEADER outcome record in high-risk diabetes, and it pairs well with exercise.

Dependency/Withdrawal (High): The trials and label reviewed here describe no craving or dose-escalation pattern with liraglutide. The score reflects functional dependence: for many people, weight and appetite drift back after treatment stops, and in type 2 diabetes glucose tends to rise again. Liraglutide therefore behaves more like a long-term therapy for a chronic condition than a short course, although exercise habits built during treatment can help preserve part of the result.

Reversibility (Low): Liraglutide itself clears quickly. With a half-life of about 13 hours, most of the drug is gone within a few days of the last dose, and its gastrointestinal effects usually ease after stopping. The evidence reviewed here doesn't establish a lasting physiological change caused by the drug itself. The rare serious harms, pancreatitis and gallbladder disease, are scored under Safety, and weight regain after stopping is scored under Durability rather than here.

Is Liraglutide worth it?

Liraglutide is a well-studied prescription option with its clearest case in type 2 diabetes, especially at high cardiovascular risk, where LEADER supplies outcome evidence few metabolic drugs can match. For weight management alone, it produces moderate average weight loss, and independent reviewers rate several obesity outcomes with limited certainty. Daily injections, common nausea and a higher dropout rate than weekly semaglutide keep it from ranking higher, which is why the score of 5.0–5.5/10 lands in the middle. The safety profile is acceptable for indicated patients under supervision but not trivial, because pancreatitis can be serious and gallbladder disease becomes more common with rapid weight loss. Anyone with medullary thyroid carcinoma or MEN 2 in the family shouldn't use it. Liraglutide is a prescription medicine for defined conditions, and nothing in this report supports using it outside a prescriber's care or from unregulated supply.

✅ Best for: Adults with type 2 diabetes and established or high cardiovascular risk, where liraglutide's LEADER outcome data apply directly; adults with obesity, or overweight plus a weight-related condition, whose prescriber has a specific reason to choose a daily GLP-1 receptor agonist; adolescents 12 and older who weigh more than 60 kg and have obesity, under a pediatric specialist and the label's 12-week BMI check; adults with prediabetes and obesity who want to lower their diabetes risk and accept ongoing treatment; and people prepared to pair treatment with resistance training and adequate protein.

❌ Avoid if: You or a close relative has had medullary thyroid carcinoma or MEN 2; you've had pancreatitis or have active gallbladder disease without specialist input; you're pregnant or planning pregnancy; you have severe gastroparesis; you take insulin or a sulfonylurea without a plan to adjust doses; you're seeking it for a child under 12 for weight, since that use is research evidence rather than current labeled care; or you're considering gray-market or compounded supply, where identity and dose accuracy can't be assumed.

What is Liraglutide best for?

The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.

Body Composition / Fat Loss: 6.5/10

Score: 6.5/10

Liraglutide produces real, moderate weight loss in adults with obesity. In the 3,731-person SCALE trial, 3.0 mg daily plus lifestyle counseling cut weight by 8.4 kg versus 2.8 kg on placebo over 56 weeks (Pi-Sunyer 2015). The independent Cochrane review of 24 trials judged with moderate certainty that liraglutide roughly doubles the chance of losing at least 5% of body weight, while rating the pooled average weight change as very low certainty. Lean tissue can be lost along with fat, which is why protein intake and resistance training are standard companions. Weight often returns after stopping, so the benefit is best read as a treatment-period effect.

Blood Sugar / Glycemic Control: 7.5/10

Score: 7.5/10

Glycemic control is liraglutide's original and best-established use. Over two years of monotherapy, 1.8 mg daily lowered HbA1c by 1.1% in completers versus 0.6% on glimepiride, with less minor hypoglycemia; the first year was double-blind and the second open-label (Garber 2011). In adults with prediabetes, three years of the 3.0 mg dose cut new diabetes diagnoses to 2% versus 6% on placebo, a hazard ratio of 0.21, although about half of participants did not complete the study (le Roux 2017). Because insulin release is glucose-dependent, liraglutide alone rarely causes hypoglycemia, although insulin or sulfonylurea combinations change that.

Metabolic Health: 7.0/10

Score: 7.0/10

Liraglutide moves several linked metabolic outcomes at once, which is why this use case scores well. SCALE Diabetes showed 6.0% weight loss at 3.0 mg versus 2.0% on placebo in 846 adults with type 2 diabetes (Davies 2015), and the prediabetes extension delayed progression to diabetes substantially. The small LEAN trial also found more resolution of steatohepatitis than placebo. Most of these gains track weight and glucose improvement rather than separate drug effects. Liraglutide does not replace blood-pressure treatment, lipid therapy, nutrition or exercise when those are the dominant problem, and the Cochrane review found little to no difference in quality of life.

Cardiovascular: 7.0/10

Score: 7.0/10

Liraglutide has a positive hard cardiovascular outcome trial in a specific population. In LEADER, 9,340 people with type 2 diabetes and high cardiovascular risk had fewer major cardiovascular events on liraglutide, a hazard ratio of 0.87, with lower cardiovascular and all-cause death over a median 3.8 years (Marso 2016). That result does not transfer automatically to obesity without diabetes: the Cochrane obesity review found likely little to no difference in major cardiovascular events across six trials. In advanced heart failure with reduced ejection fraction, the FIGHT trial found no benefit. The score credits the high-risk diabetes evidence while staying below the top range.

Kidney Function: 5.5/10

Score: 5.5/10

Liraglutide has secondary-outcome kidney data from a large trial. In LEADER, the renal composite fell with a hazard ratio of 0.78, driven mainly by fewer cases of new persistent macroalbuminuria, while acute kidney injury rates were similar between groups (Mann 2017). The score sits mid-range because this was a secondary analysis in type 2 diabetes with high cardiovascular risk rather than a dedicated kidney trial, and because the benefit rests mostly on albuminuria rather than hard loss of kidney function. Severe vomiting or diarrhea can cause dehydration and acute kidney injury, which is why the label flags renal impairment.

Pediatric Use: 5.0/10

Score: 5.0/10

Liraglutide has randomized adolescent weight data and a pediatric weight-management label for ages 12 and older with body weight above 60 kg and obesity. In 251 adolescents, 3.0 mg daily plus lifestyle therapy lowered BMI standard deviation score by 0.22 more than placebo over 56 weeks (Kelly 2020). The label adds a stopping rule: check BMI after 12 weeks on the maintenance dose. A separate trial in children aged 6 to under 12 is research evidence only, not current labeled obesity care. The type 2 diabetes label covers glycemic control from age 10, not general pediatric use. Decisions belong with a pediatric specialist.

Use CaseScoreSummary
○ Liver / Detoxification4.5The small LEAN phase 2 trial found steatohepatitis resolution in 9 of 23 people on liraglutide versus 2 of 22 on placebo, a promising but imprecise result that needs larger confirmation.
○ Healthspan4.5Lower cardiovascular death in high-risk diabetes, delayed diabetes and moderate weight loss may support healthspan in indicated patients, but no trial in this report's evidence set measures healthspan directly.
○ Respiratory4.0In SCALE Sleep Apnea, liraglutide lowered the apnea-hypopnea index by 6.1 events per hour more than placebo, a modest weight-linked improvement rather than a dedicated apnea treatment.
○ Sleep Quality3.5Any sleep benefit runs through weight-related sleep apnea improvement, which was modest in the SCALE Sleep Apnea trial; liraglutide is not a sleep treatment in its own right.
○ Geriatric / Aging Population3.5Older adults with type 2 diabetes were well represented in LEADER; during weight loss, clinicians typically watch protein intake, strength and frailty in this group.
○ Hormonal / Endocrine3.5In women with obesity and polycystic ovary syndrome, liraglutide 3 mg improved weight and some hormonal and metabolic markers in a randomized trial; effects appear to follow fat loss.
○ Anti-Inflammatory3.0Inflammatory markers improve alongside weight loss in liraglutide trials, but the effect appears largely downstream of fat loss.

Frequently Asked Questions

How does liraglutide work?

Liraglutide mimics the gut hormone GLP-1 and activates its receptor, which increases insulin release only when glucose is high, suppresses glucagon, slows stomach emptying and reduces appetite. Its fatty-acid side chain binds albumin and stretches the half-life to about 13 hours, which is why it's a once-daily injection rather than weekly. The current FDA label describes these actions and the dosing schedule for weight management.

How much weight do people lose on liraglutide?

In the 56-week SCALE trial of 3,731 adults without diabetes, liraglutide 3.0 mg with lifestyle counseling produced 8.4 kg average weight loss versus 2.8 kg on placebo, and 63.2% lost at least 5% of body weight (Pi-Sunyer 2015). An independent Cochrane review found liraglutide roughly doubles the odds of reaching 5% loss with moderate certainty, but rated the pooled average change very low certainty (Meza 2025). People with type 2 diabetes tend to lose less.

Is liraglutide or semaglutide better for weight loss?

Semaglutide produced more weight loss in the only head-to-head trial. In STEP 8, 338 adults with overweight or obesity and no diabetes were followed for 68 weeks; weekly semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% on daily liraglutide 3.0 mg, and fewer people stopped semaglutide (13.5% versus 27.6%) (Rubino 2022). Liraglutide can still be reasonable when a prescriber has a specific reason. The semaglutide report covers the weekly option.

Does liraglutide protect the heart?

In people with type 2 diabetes and high cardiovascular risk, the evidence says yes. The LEADER trial of 9,340 patients found fewer major cardiovascular events on liraglutide, with a hazard ratio of 0.87 over a median 3.8 years, plus lower cardiovascular and all-cause death (Marso 2016). In obesity without diabetes, the Cochrane review found likely little to no difference in major cardiovascular events, and a trial in advanced heart failure with reduced ejection fraction found no benefit.

Is liraglutide safe long term?

Liraglutide has about four years of outcome-trial follow-up and more than a decade of prescription use; its main serious risks are acute pancreatitis (including rare fatal cases), gallbladder disease and dehydration-related kidney injury. The thyroid C-cell tumor warning comes from rodents, and human studies disagree: a French case-control study found higher risk (Bezin 2023) while a large Scandinavian cohort found none (Pasternak 2024).

Who should not take liraglutide?

Liraglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, or a prior serious hypersensitivity reaction to it, per the current label. It needs extra caution after pancreatitis, with gallbladder disease, severe gastroparesis, kidney impairment, or alongside insulin or a sulfonylurea. It's stopped when pregnancy is planned. A prescriber should check these against the full label before starting.

How quickly does liraglutide start working?

Appetite and glucose usually shift within the first one to two weeks, while weight loss builds over several months. For adults, the weight-management label says to evaluate weight 16 weeks after starting and stop if loss is under 4%. For adolescents, the check comes after 12 weeks on the maintenance dose, using a 1% BMI reduction. In the SCALE trial, most of the loss accrued in the first months (Pi-Sunyer 2015).

What happens when you stop liraglutide?

Weight often returns, though not always fully. A pooled analysis across weight-management drugs found regain of about 0.4 kg per month after stopping (West 2026). In a Copenhagen trial follow-up, people who had combined liraglutide with supervised exercise kept off 5.1 kg more a year after stopping than those who had taken liraglutide alone (Jensen 2024). Only 109 participants attended that follow-up, so treat it as encouraging rather than settled.

What could change Liraglutide's score?

BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.

The most plausible movement for liraglutide is small, and the direction depends on which question new evidence answers. Independent, non-manufacturer trials that raise the Cochrane certainty for average weight change and serious adverse events would strengthen Evidence, currently Strong. Long-term data showing that exercise or other maintenance strategies reliably hold weight after stopping would raise Durability, currently Limited. An outcome trial of the 3.0 mg weight dose in people without diabetes would test whether the LEADER cardiovascular benefit extends beyond high-risk diabetes and could widen Breadth. In the other direction, independent cohorts confirming a causal human thyroid cancer risk would add to Safety concerns, and a Cochrane update confirming more serious adverse events would push the downside up. Because liraglutide's evidence base is mature, a single study should move the score by tenths rather than whole points, and only a consistent pattern should move it further.

  • Independent trials raise certainty for weight and safety outcomes: Evidence moves up; the overall score rises modestly.
  • Maintenance strategies are shown to prevent regain after stopping: Durability moves up; the overall score rises modestly.
  • A cardiovascular outcome trial succeeds in obesity without diabetes: Breadth and Evidence move up; the overall score rises modestly.
  • Independent cohorts confirm a causal human thyroid cancer risk: Safety concern rises; the overall score falls.
  • Updated reviews confirm more serious adverse events at higher certainty: Safety and Side Effects concerns rise; the overall score falls.

Key Evidence Sources

What does the evidence say about Liraglutide?

Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.

Modern Clinical Research

Confidence: Medium

Modern evidence for liraglutide is large but uneven in certainty. The SCALE program showed 8.4 kg mean weight loss versus 2.8 kg on placebo over 56 weeks in 3,731 adults. An independent Cochrane review of 24 obesity trials (9,937 participants) found with moderate certainty that liraglutide roughly doubles the chance of losing 5% of body weight, yet rated the pooled average weight change very low certainty and serious adverse events low certainty. Twenty-two of those trials were manufacturer-funded. LEADER, a separate 9,340-person outcome trial in high-risk type 2 diabetes, lowered major cardiovascular events with a hazard ratio of 0.87, while the Cochrane obesity analysis found likely little to no difference in such events. Head to head in STEP 8, weekly semaglutide produced more weight loss with fewer dropouts. The Alzheimer's ELAD trial missed its primary endpoint, and a heart failure trial was null. Certainty is strongest for glucose control and cardiovascular outcomes in type 2 diabetes.

Citations: Pi-Sunyer 2015, Meza 2025, Marso 2016, Rubino 2022

Pre-RCT-Era Pharmacology and Use

Confidence: Limited

Liraglutide has no pre-modern history of use. It is a synthetic analogue of human GLP-1 with a fatty-acid side chain, designed in a pharmaceutical laboratory, so no historical population ever took it. Its only history is its own clinical record. Early dose-ranging work in obesity tested 1.2 to 3.0 mg against placebo and orlistat in 564 adults over 20 weeks, and two-year monotherapy data in type 2 diabetes showed glycemic control holding better than with glimepiride, with the second year run open-label. Since its first approval for type 2 diabetes, liraglutide has accumulated more than a decade of prescription use, postmarketing surveillance and label revisions. That record is useful for spotting rare harms and confirming durability on treatment. It should not be confused with a historical lineage. The long evolutionary history of the native hormone says nothing about the long-term safety of a pharmaceutical analogue at therapeutic doses.

Citations: Astrup 2009, Garber 2011

Traditional Medicine Systems

Confidence: Limited

No traditional medical system describes liraglutide, and this report does not construct a lineage for it. Traditional Chinese medicine, Ayurveda and European folk medicine all discuss appetite, digestion and satiety, but none administered a gut hormone analogue, and drawing a straight line from those practices to an engineered peptide would be invented history. The honest position is an empty lens. Liraglutide's use is defined entirely by modern prescribing information, which sets its indications, titration, contraindications and warnings, from the rodent-derived thyroid C-cell tumor boxed warning to the risk of pancreatitis. Readers who value traditional dietary practices can still use them alongside treatment, for example by prioritizing protein and fiber when appetite falls, but those practices neither validate nor contradict the drug. The benefit and risk of liraglutide rest on the clinical trials and the regulatory record described in the modern lens, and this lens adds no independent credit or caution.

Citations: DailyMed 2026

Holistic Evidence for Liraglutide

Only the modern clinical lens speaks directly to liraglutide. The historical lens is the drug's own short clinical record, and the traditional lens is honestly empty, so neither adds independent support or caution.

What to Track If You Try This

These are the data points that matter most while running a 30-day Experiment with this intervention.

How to read this section
Pre
Test or score before starting the protocol. Anchors a baseline.
During
Track while running the protocol so you can see if anything is changing.
Post
Re-test after a full cycle to confirm the change held.
Up
The marker should rise. For most positive outcomes, that is a good sign.
Down
The marker should fall. For most positive outcomes, that is a good sign.
Stable
The marker should hold steady. Big swings in either direction are a yellow flag.
Watch
Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
N/A
No expected direction. The entry is there to anchor a baseline reading.
Primary
The Pulse dimension most likely to shift. Track this first.
Secondary
Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.

Bloodwork to Order

Open These Markers In Your Dashboard

  • HbA1c Baseline (pre-protocol)
  • Fasting Glucose During | Expected Down
  • Blood Pressure During | Expected Down
  • Resting Heart Rate During | Expected Watch
  • eGFR During | Expected Stable
  • Lipase During | Expected Watch

Pulse Dimensions to Watch

  • Body During | Expected Down | Primary
  • Energy During | Expected Watch | Secondary
  • Calm During | Expected Watch | Tertiary

Subjective Signals (Daily Voice Card)

  • Early satiety and fullness Scale 1-5 | During | Expected Up
  • Appetite between meals Scale 1-5 | During | Expected Down
  • Nausea after the daily dose Scale 1-5 | During | Expected Watch
  • Protein intake and resistance-training consistency Scale 1-5 | During | Expected Up

Red Flags: Stop and Consult

  • Severe upper abdominal pain radiating to the back, with or without vomiting: stop and seek urgent care for a pancreatitis check.
  • Personal or family history of medullary thyroid carcinoma or MEN 2: liraglutide is contraindicated.
  • A neck lump, hoarseness or trouble swallowing: get it evaluated.
  • Shakiness, sweating or confusion while also using insulin or a sulfonylurea: treat low blood sugar and have doses reviewed.
  • Persistent vomiting or diarrhea with signs of dehydration: seek care, since dehydration can injure the kidneys.
  • Right upper abdominal pain, fever or yellowing skin: get a gallbladder assessment.

Other interventions for Body Composition

Strength / Resistance Training 8.5–9.0 💪 Grass-Fed Whey Protein 8.0–8.5 💪 Essential Amino Acids 7.5–8.0 💪
See all ratings →
📊 How BioHarmony scoring works

BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.

Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.

Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.

Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.

EV = Upside − Downside
EV = 2.725 − 2.566 = 0.159
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.159 / 4.00) × 5 = 5.2 / 10

See the full BioHarmony methodology →

This report is educational and informational. It is not medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new supplement, device, protocol, or intervention, particularly if you take prescription medications, have a chronic health condition, are pregnant or nursing, or are under 18.